Results 121 to 130 of about 346,212 (321)

IL-17 can be protective or deleterious in murine pneumococcal pneumonia [PDF]

open access: yes, 2018
Streptococcus pneumoniae is the major bacterial cause of community-acquired pneumonia, and the leading agent of childhood pneumonia deaths worldwide. Nasal colonization is an essential step prior to infection.
Bayes, Hannah K.   +4 more
core   +3 more sources

High‐Resolution Characterization of Protein‐Conjugated, mRNA‐Loaded Lipid Nanoparticles by Analytical Ultracentrifugation

open access: yesAdvanced Functional Materials, EarlyView.
Lipid nanoparticles containing messenger RNA are characterized by sedimentation velocity analytical ultracentrifugation using UltraScan's new Custom Grid algorithm to provide multi‐dimensional distributions for partial specific volume (particle density), molar mass, sedimentation, diffusion, and hydrodynamic radius.
Sophia Bird   +8 more
wiley   +1 more source

Neonatal Immunization: Rationale, Current State, and Future Prospects

open access: yesFrontiers in Immunology, 2018
Infections take their greatest toll in early life necessitating robust approaches to protect the very young. Here, we review the rationale, current state, and future research directions for one such approach: neonatal immunization. Challenges to neonatal
Elizabeth Whittaker   +4 more
doaj   +1 more source

Analysis of black holes in our knowledge concerning animal health in the organic food production chain [PDF]

open access: yes, 2003
Although a large body of research on health aspects can be found via the web or in conference proceedings, only few papers reach the peer reviewed literature.
Eijck, Ineke   +4 more
core  

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. [PDF]

open access: yes, 2017
The 2014-2015 Ebola epidemic affected several African countries, claiming more than 11,000 lives and leaving thousands with ongoing sequelae. Safe and effective vaccines could prevent or limit future outbreaks.
Agnandji, ST   +17 more
core   +2 more sources

PRELIVE: A Framework for Predicting Lipid Nanoparticles In Vivo Efficacy and Reducing Reliance on Animal Testing

open access: yesAdvanced Functional Materials, EarlyView.
PREdicting LNP In Vivo Efficacy (PRELIVE) framework enables the prediction of lipid nanoparticle (LNPs) organ‐specific delivery through dual modeling approaches. Composition‐based models using formulation parameters and protein corona‐based models using biological fingerprints both achieve high predictive accuracy across multiple organs.
Belal I. Hanafy   +3 more
wiley   +1 more source

On Pediatric Vaccines and Catholic Social Teaching [PDF]

open access: yes, 2018
Determining whether, and when, to get one\u27s children vaccinated has become an increasingly controversial decision, often leaving parents fearful of making the “wrong” choice.
Bilgrien   +20 more
core   +2 more sources

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

open access: yesAdvanced Functional Materials, EarlyView.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras   +6 more
wiley   +1 more source

Poly(lactic‐co‐glycolic acid) Nanoparticles for IL‐12 Self‐Amplifying RNA Delivery in Glioblastoma Models

open access: yesAdvanced Functional Materials, EarlyView.
xxxx. ABSTRACT Glioblastoma (GBM) remains one of the most lethal brain cancers, with median survival rarely exceeding 15 months after diagnosis. Interleukin‐12 (IL‐12) is a potent immunostimulatory cytokine capable of reshaping the tumor microenvironment (TME), yet its clinical translation is hindered by systemic toxicity and short half‐life. RNA‐based
Fatima Hameedat   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy